Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse Alba M, Fintini D, Bowers CY, et al
Adults 18+ with a BMI of 27 or higher, or 25+ with weight-related conditions Patients who have plateaued on a single-agonist GLP-1 and want to escalate under supervision People for whom faster onset and higher trial averages are clinically appropriate Personal or family history of medullary thyroid carcinoma or MEN 2 Pregnancy, breastfeeding, or planning pregnancy Active pancreatitis or untreated severe gastrointestinal disease Expected Timeline What to Expect Tirzepatide tends to act faster and reach further than single-agonist GLP-1s
Because trigger foods cause an immune response, they produce inflammatory compounds that end up throughout the body, including the skin
Hormonal Balance & Metabolic Health Epithalon therapy has been shown to help regulate various hormonal systems, including those controlled by the pineal gland and hypothalamic-pituitary axis
